Mereo BioPharma Confirms Receipt of a Valid Notice Requiring it to Convene a General Meeting of Shareholders

Rubric has Rejected Mereo’s Reasonable Settlement Proposal and has Escalated its Costly, Distracting Proxy Campaign to Now Seek Control of Mereo’s Board Mereo Reiterates Support for its... | October 3, 2022

Related Keywords

United States ,United Kingdom ,London ,City Of ,America ,Michael Wyzga ,Tom Johnson Dan ,Christine Fox ,Deepa Pakianathan ,Lee Roth ,Denise Scots Knight ,Mereo Biopharma ,Abernathy Macgregor Communications Adviser To Mereo ,Ultragenyx Pharmaceutical Inc ,Mereo Biopharma Group ,Oncologie Inc ,Nasdaq ,Oncxerna Therapeutics Inc ,Exchange Commission ,United States Securities Exchange ,United Kingdom Companies ,Rejected Mereo ,Reasonable Settlement Proposal ,Distracting Proxy Campaign ,Now Seek Control ,Reiterates Support ,Highly Qualified Board ,Urges Shareholders ,Reject Rubric ,Independent Directors ,Upcoming General ,Biopharma Group ,Rubric Capital Management ,Companies Act ,General Meeting ,Annual General Meeting ,Chairman Michael Wyzga ,Mereo Board ,United Kingdom Companies Act ,Mereo Shareholders ,General Meetings ,Bronchiolitis Obliterans Syndrome ,Ultragenyx Pharmaceutical ,Drug Designation ,North America ,Oncxerna Therapeutics ,United States Securities Act ,United States Securities Exchange Act ,Annual Report ,Biopharma Contacts ,Chief Executive ,Chief Financial ,Communications Adviser ,Investor Relations Adviser ,Mereo Biopharma Group Plc Stock Exchange ,News ,Information ,Press Release ,Rubric ,Gas ,Ejected ,Reasonable ,Settlement ,Proposal ,End ,Escalated ,Its ,Rdistracting ,Proxy ,Campaign ,O ,Dow ,Eek ,Control ,F ,Board ,Wereo ,Eiterates ,Support ,Or Mph Gb00bz4g2k23 ,